Title

Optimisation of adaptive therapy for advanced Hodgkin lymphoma

UMMS Affiliation

Department of Radiation Oncology; Imaging and Radiation Oncology Core

Publication Date

2019-02-01

Document Type

Response or Comment

Disciplines

Hemic and Lymphatic Diseases | Neoplasms | Oncology | Radiation Medicine

Abstract

Comment on: PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. Casasnovas RO, Bouabdallah R, Brice P, Lazarovici J, Ghesquieres H, Stamatoullas A, Dupuis J, Gac AC, Gastinne T, Joly B, Bouabdallah K, Nicolas-Virelizier E, Feugier P, Morschhauser F, Delarue R, Farhat H, Quittet P, Berriolo-Riedinger A, Tempescul A, Edeline V, Maisonneuve H, Fornecker LM, Lamy T, Delmer A, Dartigues P, Martin L, André M, Mounier N, Traverse-Glehen A, Meignan M.Lancet Oncol. 2019 Feb;20(2):202-215. doi: 10.1016/S1470-2045(18)30784-8. Epub 2019 Jan 15.PMID: 30658935 Clinical Trial.

DOI of Published Version

10.1016/S1470-2045(19)30005-1

Source

Fitzgerald TJ. Optimisation of adaptive therapy for advanced Hodgkin lymphoma. Lancet Oncol. 2019 Feb;20(2):167-168. doi: 10.1016/S1470-2045(19)30005-1. Epub 2019 Jan 15. PMID: 30658934. Link to article on publisher's site

Journal/Book/Conference Title

The Lancet. Oncology

Related Resources

Link to Article in PubMed

PubMed ID

30658934

Share

COinS